Compare IQIYI Inc - ADR (IQ) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQIYI Inc - ADR vs Viatris Inc — how do they compare? IQIYI Inc - ADR trades at $1.02 (market cap $974.67M), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 20.6× IQIYI Inc - ADR's market cap, and Viatris Inc pays a 2.75% dividend while IQIYI Inc - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold IQIYI Inc - ADR for 55 Days and Viatris Inc for 57 Days on average.
| IQ | VTRS | |
|---|---|---|
Market Cap | $974.67M | $20.03B |
Volume | 4,964,108 | 14,109,977 |
Sector | Media | Health |
52-Week High | $2.35 | $18.27 |
52-Week Low | $0.86 | $9.74 |
Typical Hold Time | 55 Days | 57 Days |
Enterprise Value | $2.47B | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
iQIYI (IQ) trades at $1.02, up 0.49% with bearish technical signals despite recent earnings beats. The company faces revenue contraction to $27.29B in 2025 and negative net margins (-3.22%), though valuation ratios like P/S (0.25) and P/B (0.52) appear attractive. Recent news highlights AI-driven content initiatives, including the successful 'The Ferry Man' series, as management pivots to offset streaming declines.
Outlook remains challenged by sustained losses and competitive pressures, but analyst consensus leans bullish (50% Buy ratings). Key risks include execution on AI content monetization and Chinese regulatory environment. The stock's deep value profile offers speculative appeal if operational turnaround materializes.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
